Physician profile
Amy E Rutherford
NPI 1902281389
$2,320.21
in general payments reported to CMS, 2019-2025
22 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $407 · 2022: $346 · 2023: $611 · 2024: $582 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,567.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $563.13 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $360.30 | 2021-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $232.20 | 2021-2025 | |
| Pfizer INC. | $185.91 | 2021-2024 | |
| Ucb, INC. | $184.42 | 2025 | Bimzelx |
| Genzyme Corporation | $149.91 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $119.69 | 2021-2022 | |
| Amgen INC. | $95.77 | 2021-2024 | Otezla |
| Novartis Pharmaceuticals Corporation | $67.25 | 2023-2025 | |
| Galderma Laboratories, L.P. | $58.92 | 2021-2025 | Nemluvio |
| Paratek Pharmaceuticals, INC. | $49.83 | 2024-2025 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $36.15 | 2021 | |
| Lilly USA, LLC | $33.23 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $26.52 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.20 | 2023 | Spevigo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $25.02 | 2024 | Adbry |
| Vyne Pharmaceuticals INC. | $23.27 | 2021 | |
| Genentech USA, INC. | $22.25 | 2021 | |
| Arcutis Biotherapeutics, INC. | $17.35 | 2023 | |
| Organogenesis INC. | $15.32 | 2022 | |
| Allergan, INC. | $14.12 | 2021 | |
| Dermavant Sciences, INC. | $13.45 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Rutherford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.